Medipal Holdings Corporation (JP:7459)
:7459
Top Page
Medipal Holdings
(7459)
Select Model
Select Model
Rating:68Neutral
Price Target:
¥3,088.00
▲(8.47% Upside)
Action:DowngradedDate:10/30/25
Medipal Holdings' overall stock score is driven by its solid financial performance and reasonable valuation. The technical analysis indicates a bearish trend, which slightly offsets the positive financial outlook. The lack of earnings call data and corporate events does not impact the score.
Positive Factors
Robust balance sheet
Extremely low leverage and a strong equity ratio materially reduce financial risk and increase resilience to demand shocks or reimbursement changes. This durable capital structure supports sustained investment in logistics, stable dividend policy, and optionality for M&A or capex without relying on debt.
Negative Factors
Thin profitability margins
Low gross and net margins reflect the competitive, low-margin nature of pharmaceutical wholesale. Persistent thin margins limit the firm's ability to absorb cost inflation or fund margin-expanding initiatives, making long-term profit improvement dependent on operational efficiencies or higher-margin services.
Read all positive and negative factors
Positive Factors
Negative Factors
Robust balance sheet
Extremely low leverage and a strong equity ratio materially reduce financial risk and increase resilience to demand shocks or reimbursement changes. This durable capital structure supports sustained investment in logistics, stable dividend policy, and optionality for M&A or capex without relying on debt.
Read all positive factors
Medipal Holdings (7459) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥518.75B
Dividend Yield2.27%
Average Volume (3M)365.88K
Price to Earnings (P/E)9.3
Beta (1Y)0.50
Revenue Growth3.88%
EPS Growth-10.72%
CountryJP
Employees13,075
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)74.68
Shares Outstanding215,975,040
10 Day Avg. Volume365,940
30 Day Avg. Volume365,883
Financial Highlights & Ratios
PEG Ratio-8.97
Price to Book (P/B)0.79
Price to Sales (P/S)0.13
P/FCF Ratio9.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥2,700.00Price Target Upside-5.16% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)178.04
Revenue Forecast (FY)¥3.85T
Medipal Holdings Business Overview & Revenue Model
Company Description
Medipal Holdings Corporation engages in the prescription pharmaceutical wholesale business in Japan. It procures healthcare products related to diagnostics, testing, treatment, and administration comprises medical equipment and medical materials, ...
How the Company Makes Money
Medipal Holdings makes money mainly through wholesale distribution margins and service fees tied to moving healthcare products from manufacturers to healthcare customers. Its core revenue stream is the sale of prescription and over-the-counter pha...
Medipal Holdings Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
80
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.71T | 3.67T | 3.56T | 3.36T | 3.29T | 3.21T |
| Gross Profit | 244.32B | 242.25B | 233.01B | 212.12B | 205.11B | 201.49B |
| EBITDA | 74.89B | 74.03B | 65.31B | 63.62B | 59.96B | 53.37B |
| Net Income | 40.86B | 40.28B | 41.48B | 38.81B | 29.42B | 23.93B |
Balance Sheet | ||||||
| Total Assets | 1.85T | 1.82T | 1.80T | 1.70T | 1.71T | 1.68T |
| Cash, Cash Equivalents and Short-Term Investments | 246.03B | 261.41B | 230.47B | 195.03B | 261.92B | 241.52B |
| Total Debt | 38.85B | 4.17B | 1.46B | 7.38B | 38.81B | 39.83B |
| Total Liabilities | 1.09T | 1.07T | 1.06T | 1.02T | 1.06T | 1.04T |
| Stockholders Equity | 616.58B | 619.57B | 600.35B | 561.36B | 530.30B | 523.01B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 51.70B | 46.28B | 5.66B | 45.26B | 21.61B |
| Operating Cash Flow | 0.00 | 60.56B | 61.84B | 16.15B | 61.22B | 34.45B |
| Investing Cash Flow | 0.00 | -3.36B | -7.82B | -39.47B | -24.34B | -2.94B |
| Financing Cash Flow | 0.00 | -25.95B | -25.25B | -43.56B | -16.47B | -16.00B |
Medipal Holdings Technical Analysis
Neutral
2847.00
Price Trends
2890.39
Negative
2814.15
Positive
2648.46
Positive
Market Momentum
19.02
Positive
44.46
Neutral
27.50
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7459, the sentiment is Neutral. The current price of 2847 is below the 20-day moving average (MA) of 2906.67, below the 50-day MA of 2890.39, and above the 200-day MA of 2648.46, indicating a neutral trend. The MACD of 19.02 indicates Positive momentum. The RSI at 44.46 is Neutral, neither overbought nor oversold. The STOCH value of 27.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:7459.
Medipal Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ¥471.54B | 5.40 | 6.92% | 2.69% | 5.11% | -20.51% | |
69 Neutral | ¥447.23B | 14.05 | 11.37% | 3.04% | 6.32% | 8.19% | |
69 Neutral | ¥340.31B | 7.24 | 8.60% | 1.60% | 1.37% | -1.55% | |
68 Neutral | ¥518.75B | 9.27 | 6.39% | 2.27% | 3.88% | -10.72% | |
67 Neutral | ¥353.30B | 16.82 | ― | 0.41% | 15.81% | 27.05% | |
66 Neutral | ¥641.95B | 14.44 | 15.71% | 0.96% | 21.81% | 67.76% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:7459
Medipal Holdings
2,833.00
581.74
25.84%
JP:2784
Alfresa Holdings
2,461.00
420.39
20.60%
JP:9989
Sundrug Co
3,857.00
-501.89
-11.51%
JP:7649
Sugi Holdings Co
3,378.00
390.59
13.07%
JP:9987
Suzuken Co
5,968.00
1,195.76
25.06%
JP:3549
KUSURI NO AOKI HOLDINGS CO.,LTD.
3,699.00
489.97
15.27%
Medipal Holdings Corporate Events
Medipal Posts Higher Nine-Month Sales but Signals Profit Pressure for Full Year
Feb 9, 2026
Medipal Holdings reported consolidated net sales of ¥2.91 trillion for the nine months to December 31, 2025, up 3.7% year on year, while operating profit slipped 4.8% to ¥43.2 billion but ordinary profit rose 8.1% and profit attributable...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.